Table 3.
Univariate and Multivariate Survival Analysis of DFS and OS in All Patients.
| Genes | Category | N = 100 | 5-year DFS (%) | Univariate Analysis | Multivariate Analysis | 5-year OS (%) | Univariate Analysis | |||
|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | |||||
| EGFR (All) | WT | 52 | 35.5 | 55.0 | ||||||
| MUT | 48 | 33.4 | 0.610 (0.356–1.045) | 0.072 | 77.3 | 0.356 (0.149–0.847) | 0.020 | |||
| EGFR (active)a | Otherb | 57 | 31.7 | Referencec | 55.6 | |||||
| MUT | 43 | 38.6 | 0.559 (0.320–0.977) | 0.041 | 0.607 (0.335–1.100) | 0.050 | 79.1 | 0.357 (0.143–0.890) | 0.027 | |
| TP53 | WT | 60 | 41.5 | Reference | 76.9 | |||||
| MUT | 40 | 28.9 | 1.795 (1.056–3.051) | 0.031 | 1.727 (1.003–2.975) | 0.037 | 52.4 | 2.042 (0.936–4.458) | 0.073 | |
| CDKN2B | WT | 68 | 51.6 | Reference | 62.9 | |||||
| MUT | 32 | 7.1 | 2.151 (1.253–3.694) | 0.005 | 2.391 (1.376–4.155) | 0.002 | 70.9 | 0.761 (0.317–1.823) | 0.540 | |
| RB1 | WT | 79 | 36.0 | 65.4 | ||||||
| MUT | 21 | 34.3 | 1.459 (0.783–2.722) | 0.234 | 66.2 | 1.208 (0.485–3.011) | 0.685 | |||
| CDKN1B | WT | 81 | 33.8 | 61.8 | ||||||
| MUT | 19 | 40.6 | 0.948 (0.487–1.844) | 0.875 | 75.9 | 0.522 (0.179–1.524) | 0.234 | |||
| CDKN2A | WT | 83 | 44.4 | 64.7 | ||||||
| MUT | 17 | 9.9 | 1.263 (0.665–2.401) | 0.476 | 64.2 | 1.071 (0.401–2.860) | 0.892 | |||
| PTEN | WT | 83 | 33.3 | 63.6 | ||||||
| MUT | 17 | 47.1 | 1.092 (0.533–2.236) | 0.810 | 72.1 | 0.880 (0.303–2.559) | 0.815 | |||
| ARID1A | WT | 83 | 30.9 | 63.6 | ||||||
| MUT | 17 | 58.8 | 0.811 (0.382–1.722) | 0.585 | 71.7 | 1.196 (0.449–3.185) | 0.721 | |||
| APC | WT | 84 | 37.9 | 63.8 | ||||||
| MUT | 16 | 29.5 | 1.061 (0.533–2.110) | 0.866 | 65.6 | 1.295 (0.516–3.254) | 0.582 | |||
| STK11 | WT | 85 | 39.5 | 67.2 | ||||||
| MUT | 15 | 18.8 | 1.707 (0.858–3.395) | 0.128 | 46.7 | 1.793 (0.672–4.782) | 0.243 | |||
| FBXW7 | WT | 87 | 30.3 | 63.6 | ||||||
| MUT | 13 | 65.9 | 0.511 (0.203–1.288) | 0.155 | 72.5 | 1.131 (0.386–3.315) | 0.822 | |||
| KRAS | WT | 88 | 37.0 | 71.9 | ||||||
| MUT | 12 | 25.0 | 1.947 (0.950–3.992) | 0.069 | 44.4 | 2.277 (0.910–5.696) | 0.078 | |||
| ACVR2A | WT | 88 | 33.7 | 63.2 | ||||||
| MUT | 12 | 56.3 | 0.493 (0.178–1.366) | 0.174 | 83.3 | 0.631 (0.149–2.680) | 0.533 | |||
Note: Only those genes mutated in more than 12 patients were analyzed. aActive EGFR mutation refers to exon19 deletion or L858R point mutations. bOther refers to patients with wildtype EGFR or non-active EGFR mutations. cMultivariate analysis was performed for the EGFR active mutation group, since the data for those with active mutations and those with any EGFR mutation overlapped considerably. DFS, disease-free survival; OS, overall survival; N, number; HR, hazard ratio; CI, confidence interval; WT, wildtype; Mut, mutated; Bold values are those with statistical significance of p < 0.05.